# US 10,869,841 B2 · Nanoscale coatings for encapsulation of biological entities > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,841 B2 - Document ID: US10869841B2 - Status: Granted - Kind: B2 - Application number: 16/255,709 - Filed: 2019-01-23 - Published: 2019-05-23 - Granted: 2020-12-22 - Earliest claimed: 2013-04-18 - Assignees: The Regents of the University of California - Applicants: The Regents of the University of California - Inventors: Inanc Ortac; Gen Yong; Michael Benchimol; Sadik C. Esener - Web page: https://patentgrep.com/patent/US10869841B2 ## CPC - A61K 9/5192: {Processes} - A61K 9/5115: {Inorganic compounds} - A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides} - A61K 35/76: Viruses; Subviral particles; Bacteriophages - A61P 35/00: Antineoplastic agents - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica. ## Claims ### Claim 1 A bioactive virus delivery device, comprising: an interior polymer material and virus, wherein the polymer material is bound to the surface of the virus via an electrostatic interaction; and an exterior silica gel matrix formed directly on the surface of the interior polymer material and virus to envelope, encapsulate, and preserve biological activity of the virus, wherein an outer surface of the silica gel matrix comprises a secondary functionalization, wherein the exterior silica gel matrix does not include the interior polymer material, and wherein encapsulation of the virus by the silica gel matrix protects the virus from immune recognition and neutralization during a viral therapy. ### Claim 2 (depends on 1) The device of claim 1, wherein the exterior silica gel matrix protects the virus from degradation from external environmental factors including pH, temperature, pressure, and chemical substances in an environment where the bioactive virus delivery device is deployed. ### Claim 3 (depends on 1) The device of claim 1, wherein the secondary functionalization is a tumor targeting ligand to cause the bioactive virus delivery device to selectively accumulate in a tumor region over other tissues. ### Claim 4 (depends on 1) The device of claim 1, wherein the secondary functionalization is an agent to increase circulation time by reducing uptake from undesired body tissues, organs, and systems, the agent including at least one of polyethylene glycol, a zwitterionic compound, or a patient-specific coating such as cell membranes. ### Claim 5 (depends on 1) The device of claim 1, wherein: the secondary functionalization includes an external coating formed of polyethylene glycol (PEG) on the outer surface of the exterior silica gel matrix, the external coating capable of preventing an immune system response within a living organism when the device is deployed. ### Claim 6 (depends on 1) The device of claim 1, wherein: the secondary functionalization includes a targeting ligand formed on the outer surface of the exterior silica gel matrix, the targeting ligand capable of selectively binding to a particular region of a cell or tissue of a living organism when the device is deployed. ### Claim 7 (depends on 1) The device of claim 1, wherein the secondary functionalization is selected from the group consisting of: PEG, folate, pH sensitive PEG, affibodies, antibodies, IgG, IgM, VEGF-C, cRGD, DNA, aptamers, proteins, lipoproteins, apolipoproteins, glycoproteins, glycans, carbohydrates, saccharides, oligosaccharides, polymers, oligomers, and lipids. ### Claim 8 (depends on 1) The device of claim 1, wherein the secondary functionalization is PEG. ### Claim 9 (depends on 1) The device of claim 1, wherein the secondary functionalization is folate. ### Claim 10 (depends on 1) The device of claim 1, wherein the secondary functionalization is PEG and folate.